Eribulin Treatment as 1st-line or 2nd-line Chemotherapy for HER2-negative Hormone-resistant Inoperable or Recurrent Metastatic Breast Cancer

NCT02551263 | Completed

• 2 other identifiers: TRIBC1505UMIN000018178
• Study Type: observational
• Target: 201
• Locations: 1 country
• Sites: 2

Brief Summary

This is a observational study in a real-world setting, not requiring determining a dosage regimen, dose reduction criteria, rest period criteria and withdrawal criteria. The purpose of the study is to investigate the efficacy of eribulin as the first or second line chemotherapy to prolong overall survival and to explore factors affecting the survival in patients with HER2-negative hormone-resistant inoperable or recurrent metastatic breast cancer who scheduled to receive the first or second line chemotherapy in clinical practice in Japan. The total duration of the study will be a maximum of 5 years, consisting of 2-year enrollment period and 3-year observational period; the duration of patient participation will be 3 years. All patients will receive adequate treatment for breast cancer which selected by the primary physician after enrollment using the Japanese Breast Cancer Society Clinical Practice Guideline of Breast Cancer and the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Investigators at the investigational sites will enter patient data into an electronic data capture (EDC) system up to the third chemotherapy in the study. The end of the study is defined as the time the last patient completes observational period. Patients will primarily be assessed by overall survival (OS) of the first line chemotherapy.

Conditions

Breast Cancer

Keywords

Breast Cancer; Eribulin; HER2-negative; hormone-resistant; inoperable; recurrent metastatic

Outcome Measures

Primary Outcomes (1)

• Overall survival (OS) of the first line chemotherapy

  From starting date of the first line chemotherapy until date of death from any cause (up to 5 years)

Secondary Outcomes (7)

• Overall survival (OS) of the second and third line chemotherapy

  From starting date of each line of chemotherapy until date of death from any cause (up to 5 years)

• Progression-free survival (PFS) of the first, second and third line chemotherapy

  From starting date of each line of chemotherapy until the date of first documented disease progression or date of death from any cause, whichever comes first (up to 5 years)

• Post progression survival (PPS) of the first, second and third line chemotherapy

  From the date of first documented disease progression in each line of chemotherapy until date of death from any cause (up to 5 years)

• Time to treatment failure (TTF) of the first, second and third line chemotherapy

  From starting date of each line of chemotherapy until date of discontinuation of study treatment for any reason including disease progression, treatment toxicity or death (up to 5 years)

• New metastasis-free survival (nMFS) of the first, second and third line chemotherapy

  From starting date of each line of chemotherapy until the date of first documented disease progression due to appearance of a new metastasis or date of death from any cause, whichever comes first (up to 5 years)

Study Arms (1)

Observational group

All patients will receive adequate treatment for breast cancer which selected by the primary physician after enrollment using the Japanese Breast Cancer Society Clinical Practice Guideline of Breast Cancer and the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Investigators at the investigational sites will enter patient data into an electronic data capture (EDC) system up to the third chemotherapy in the study.

Drug: Eribulin

Interventions

Eribulin DRUG

Eribulin 1.4 mg/m2 will be administered intravenously over 2 to 5 minutes on day 1 and 8 of every 21-day cycle, in a real-world setting.

Observational group

Eligibility Criteria

• Age: 20 Years - 75 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Female patients with HER2-negative hormone-resistant inoperable or recurrent metastatic breast cancer, who are scheduled to receive the first or second line chemotherapy in clinical practice in Japan.

You may qualify if:

• Female patients with histologically or cytologically confirmed breast cancer.
• Patients with inoperable or recurrent metastatic breast cancer regardless of the metastatic site and number, excluding symptomatic central nervous system metastases.
• Patients with HER2-negative disease confirmed as ISH negative or IHC 0, 1+ or 2+ (Those with IHC 2+ are eligible, if the additional ISH test results are negative. Those are ineligible who are with any positive results of estrogen receptor or progesterone receptor test on primary and recurrent lesion).
• Patients who are resistant to hormone therapy.
• Patients with indication for the first or second line chemotherapy in HER2-negative hormone-resistant inoperable or recurrent metastatic breast cancer who are scheduled to receive the chemotherapy.
• Patients with the Eastern Cooperative Oncology Group (ECOG) performance status score 0-3 at the time of enrollment.
• Patients with adequate bone marrow and major organ function judged by the primary physician.
• Patients who have signed written informed consent to participate in this study.

You may not qualify if:

• Patients with symptomatic metastasis in the central nervous system.
• Patients with a previous history of hypersensitivity to any component of drugs which will be administered in the treatment.
• Patients who are considered to be inappropriate for the study participation by the primary physician.

Sponsors & Collaborators

• Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan: lead
• Kyoto Breast Cancer Research Network: collaborator

Study Sites (2)

Kobe City Medical Center General Hospital

Kobe, Hyōgo, 650-0047, Japan

Location

Kyoto University Hospital

Kyoto, Kyoto, 606-8507, Japan

Location

MeSH Terms

Conditions

Breast Neoplasms; Neoplasm Metastasis

Interventions

eribulin

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases; Neoplastic Processes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Yuichiro Kikawa, MD

  Kobe City Medical Center General Hospital

  PRINCIPAL INVESTIGATOR

• Takeshi Kotake, MD

  Kyoto University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 15, 2015
• First Posted: September 16, 2015
• Study Start: July 22, 2015
• Primary Completion: July 1, 2020
• Study Completion: July 1, 2020
• Last Updated: June 11, 2021

Record last verified: 2021-04

Locations

JP (2)